卡维地洛和美托洛尔对病毒性心肌炎小鼠IL-12 与IFN-γ表达水平的影响

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (10): 1101-1105.

卡维地洛和美托洛尔对病毒性心肌炎小鼠IL-12 与IFN-γ表达水平的影响

李岳春¹, 陈鹏¹, 革丽莎², 任江华³

¹温州医学院附属第二医院心内科, ²儿科, 温州 325000, 浙江;
³武汉大学中南医院心内科, 武汉 430071, 湖北

收稿日期:2009-05-19 修回日期:2009-09-19 发布日期:2020-10-29
通讯作者: 陈鹏,男,硕士,副主任医师,研究方向:心血管药理学。Tel:057788086212 E-mail:wzcpu@163.com
作者简介:李岳春,男,硕士,助理教师,研究方向:炎症性心脏病。Tel:1361677696 E-mail:liyuechun1980 @sina.com.cn
基金资助:
温州市科技局基金资助项目(Y20080124)

Effects of carvedilol on the activities of IFN-γand IL-12 and oxygen free radical in murine model with coxsackievirus B3-induced viral myocarditis

LI Yue-chun¹, CHEN Peng¹, GE Li-sha², REN Jiang-hua³

¹Department of Cardiology, 2Department of Paediatrics, Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, Zhejiang, China;
3Department of Cardiology, Wuhan University Zhongnan Hospital, Wuhan 430071, Hubei, China

Received:2009-05-19 Revised:2009-09-19 Published:2020-10-29

摘要/Abstract

摘要： 目的对比研究卡维地洛和美托洛尔对柯萨奇B3 (CVB₃) 病毒性心肌炎小鼠的作用。方法随机将110 只雄性BALB/C 小鼠分为4 组:正常对照组(n =20), 心肌炎组(n =30), 卡维地洛组(n=30) 与美托洛尔组(n =30)。后3 组经腹腔接种CVB₃ 诱发急性心肌炎, 感染24 h 后卡维地洛组与美托洛尔组分别每日灌胃给予卡维地洛10 mg/kg 、美托洛尔30 mg/kg, 直至第14 天末, 分别于接种第7 天和第14 天随机从各组抽取若干只小鼠取血后处死并留取心脏等标本。结果卡维地洛组显著减轻心脏病理损伤, 显著降低心脏重量身体重量(HW/BW) 比值, 但美托洛尔组与心肌炎组比较无统计学差异;卡维地洛干预后第7 天小鼠心肌IFN-γ与IL-12 含量显著升高, MDA含量显著降低, 但美托洛尔组与心肌炎组比较无统计学差异;干预后第14 天卡维地洛组SOD 含量显著增加、MDA 含量显著降低, 美托洛尔组SOD 和MDA 含量与心肌炎组比较无统计学差异。结论卡维地洛通过增加心肌IFN-γ与IL-12 表达以及抗氧化损伤的作用, 减轻心肌炎小鼠的心肌损害, 起到保护性作用, 而美托洛尔无类似作用。

关键词: 卡维地洛, 美托洛尔, 干扰素Ⅱ型, 白细胞介素12, 抗氧化剂, 心肌炎

Abstract: AIM: The study was designed to examine the effects of carvedilol and metoprolol in a murine model of viral myocarditis induced by coxsackievirus B3 virus infection (CVB₃). METHODS: BALB/C mice were intraperitoneally inoculated with CVB₃, at the starting 24 h after infection carvedilol was administered orally in a dose of 10 mg°kg^-1°d^-1, and metoprolol was administered orally in a dose of 30 mg°kg^-1°d^-1 for 7 or 14 consective days.Virus infection group and normal group were used with same dose PBS.Mice were killed at day 7 and 14.Myocardial histopathology changes, the HW/BW ratio, the myocardial IFN-γand IL-12 production, the content of maleic dialdehyde (MDA) and superoxide dismutase (SOD) were detected. RESULTS: Carvedilol, but not metoprolol, markedly attenuated myocardial lesions and decreased HW/BW ratio.On day 7, carvedilol group, but not metoprolol group, increased the myocardial IFN-γand IL-12 production and decreased the content of MDA more significantly than virus infection group.On day 14, carvedilol group, but not metoprolol, markedly increased the content of SOD and manifested decreased the content of MDA than virus infection group. CONCLUSION: Carvedilol protects against CVB₃-induced viral myocarditis in mice.Carvedilol exerts some of its beneficial effects by boosting the production of IFN-γ and IL-12 and inhibiting peroxidants.

Key words: carvedilol, metoprolol, interferon type, IL-12, antioxidants, myocarditis

中图分类号:

R965.2

李岳春, 陈鹏, 革丽莎, 任江华. 卡维地洛和美托洛尔对病毒性心肌炎小鼠IL-12 与IFN-γ表达水平的影响[J]. 中国临床药理学与治疗学, 2009, 14(10): 1101-1105.

LI Yue-chun, CHEN Peng, GE Li-sha, REN Jiang-hua. Effects of carvedilol on the activities of IFN-γand IL-12 and oxygen free radical in murine model with coxsackievirus B3-induced viral myocarditis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1101-1105.

参考文献

[1] Pauschinger M, Doerner A, Kuehl U, et al.Eneroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis [J].Circulation, 1999, 99(7):889-895.
[2] Panina-Bordignon P, Mazzeo D, Lucia PD, et al.Beta2- agonists prevent Th1 development by selective inhibition of interleukin-12[J].J Clin Invest, 1997, 100(6):1513-1519.
[3] Andrade-Mena CE.Inhibition of gamma interferon synthesis by catecholamines[J].J Neuroimmunol, 1997, 76(1):10-14.
[4] Dulin B, Abraham WT.Pharmacology of carvedilol[J]. Am J Cardiol, 2004, 93(Suppl):3B-6B.
[5] Poole-Wilson PA, Swedberg K, Cleland JGF, et al.Comparison of carvediol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial(COMET):randomized controlled trial[J].Lancet, 2003, 362(9390):7-13.
[6] Yaoita H, Sakabe A, maehara K, et al.Different effect of carvedilol, metoprotol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats[J].Circulation, 2002, 105(8): 975-980.
[7] Henke A, Wagner E,Whitton JL, et al.Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization[J].J Viro, l998, 72(10):8327-8331.
[8] Henke A, Zell R, Stelzner A.DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice[J]. Antiviral Res, 2001, 49(1):49-54.
[9] Feldman AM, McNamara D.Myocarditis[J].N Engl J Med, 2000, 343(19):1388-1398.
[10] Tschö pe C, Westermann D, Steendijk P, et al.Hemody-Chin J Clin Pharmacol Ther 2009 Oct;14(10) namic characterization of left ventricular function in experimental coxsackieviral myocarditis:effect of carvedilol and metoprolol[J].EUR J Pharmacol, 2004, 491(2/3):173-179.
[11] Pauschinger M, Rutschow S, Chandrasekharan K, et al.Carvedilol improves left ventricular function in murine coxsackievirus- induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response[J].Eur J Heart Fail, 2005, 7(4):444-452.
[12] Sponer G, Bartsch W, Strein K, et al.Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties[J].J Cardiovasc Pharmacol, 1987, 9(3):317-327.
[13] Shioi T, Matsumori A, Nishio R, et al.Protective role of interleukin-12 in viral myocarditis[J].JMol Cell Cardiol, 1997, 29(9):2327-2334.
[14] Henke A, Zell R, Martin U, et al.Direct interferon-γ- mediated protection caused by a recombinant coxsackievirus B3[J].Virology, 2003, 315(2):335-344.
[15] Yuan Z, Shioji K, Nimata M, et al.Cardioprotective effects of carvedilol on acute autoimmune myocarditis[J]. Mol Cell Biochem, 2004, 259(1/2):223-228.
[16] Nakamura K, Kusano K, Nakamura Y, et al.Carvedilol decreases elevated oxidative stress in human failing myocardium [J].Circulation, 2002, 105(24):2867-2871.